Brokers Issue Forecasts for Minerva Neurosciences, Inc.’s Q1 2025 Earnings (NASDAQ:NERV)

Minerva Neurosciences, Inc. (NASDAQ:NERV) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of Minerva Neurosciences in a note issued to investors on Thursday, May 2nd. HC Wainwright analyst D. Tsao forecasts that the biopharmaceutical company will earn ($1.03) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $7.00 target price on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($3.57) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.92) EPS.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.31).

Separately, StockNews.com upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Thursday.

Minerva Neurosciences Trading Up 0.9 %

Shares of NASDAQ:NERV opened at $2.37 on Friday. The stock has a fifty day simple moving average of $2.66 and a two-hundred day simple moving average of $5.30. Minerva Neurosciences has a 12-month low of $2.29 and a 12-month high of $13.49. The stock has a market capitalization of $16.57 million, a price-to-earnings ratio of -0.51 and a beta of 0.27.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.